tbuckley/cabot-search huggingface dataset:
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Authors: Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Journal: Clinical and Molecular Hepatology (2021)

Fatty liver is now a major cause of liver disease in the Asia-Pacific region. Liver diseases in this region have distinctive characteristics. First, fatty liver is frequently observed in lean/normal-weight individuals. However, there is no standard definition of this unique phenotype. Second, fatty liver is often observed in patients with concomitant viral hepatitis. The exclusion of viral hepatitis from non-alcoholic fatty liver disease limits its value and detracts from the investigation and holistic management of coexisting fatty liver in patients with viral hepatitis. Third, fatty liver-associated hepatocellular carcinoma (HCC) is generally categorized as non-B non-C HCC. Fourth, the population is aging rapidly, and it is imperative to develop a practicable, low-intensity exercise program for elderly patients. Fifth, most patients and nonspecialized healthcare professionals still lack an awareness of the significance of fatty liver both in terms of intrahepatic and extrahepatic disease and cancer. Recently, an international expert panel proposed a new definition of fatty liver: metabolic dysfunction-associated fatty liver disease (MAFLD). One feature of MAFLD is that metabolic dysfunction is a prerequisite for diagnosis. Pertinent to regional issues, MAFLD also provides its diagnostic criteria in lean/normal-weight individuals. Furthermore, MAFLD is independent of any concomitant liver disease, including viral hepatitis. Therefore, MAFLD may be a more suitable definition for fatty liver in the Asia-Pacific region. In this review, we introduce the regional characteristics of fatty liver and discuss the advantages of MAFLD for improving clinical practice for liver disease in the region.
Abstract 9412: Establishing a Coronary Calcium Scoring Threshold as a Gateway to Invasive Testing for Firefighters Undergoing Fitness for Duty Exams
Authors: Shiela C Beroukhim Afrahimi, Shiela Beroukhim Afrahimi, April Kinninger, Matthew Budoff
Journal: Circulation (2021)

Introduction: Heart disease is the leading cause of death amongst active firefighters. Firefighters undergo exercise treadmill test as a part of fitness for duty examinations screening for heart disease. It has been previously shown that coronary artery calcium (CAC) scoring and CT angiography (CTA) together can be used cost effectively in further screening for obstructive coronary artery disease amongst firefighters. A coronary artery calcium score threshold to predict obstructive CAD however is yet to be established. Methods: Firefighters in the County of Los Angeles Fire Department underwent fitness for training tests over a twenty-year period using treadmill ECG tests for cardiac screening. Those with positive tests were referred for further evaluation with coronary calcium scoring (CCS). Individuals with a CCS of &amp;gt; 10 went on to have CTA as prior studies have shown that CCS &amp;lt; 10 is highly unlikely to correlate with obstruction. We used receiver-operating characteristic (ROC) analysis to determine the optimal sensitivity and specificity of a CCS threshold needed to predict which individuals were likely to have a CTA showing greater than 50% stenosis. Results: Annually, about 3000 firefighters undergo fitness for duty testing in Los Angeles County. In our sample population from 1999 to 2019, a total of 1425 firefighters had a positive treadmill test. All 1425 of these firefighters underwent CCS with scores varying from 0 to 1400, the distribution vastly skewed toward 0. A ROC curve analysis indicated that a CCS score of 75 was the optimal cutoff for sensitivity (82%) and specificity (62%), in predicting a stenosis greater than 50% in any segment in the CTA firefighter population. However, given the high stress associated with firefighter duty and the high mortality both on-duty and after-duty, we believe prioritization should be geared toward detection and prevention. For this reason, we chose to maximize sensitivity in our statistical analysis and determined that a CAC score of 10 (sensitivity 95%, specificity 13%) to be the most appropriate threshold. Conclusion: For future testing, a CCS threshold score of 10 can confidently be used to guide further testing for obstructive coronary artery disease with CTA.
Clinical Results of the Drepaglobe Trial for Sickle Cell Disease Patients
Authors: Elisa Magrin, Alessandra Magnani, Michaela Semeraro, Nicolas Hebert, Laure Joseph, Olivia Leblanc, Aurélie Gabrion, Cécile Roudaut, Axelle Maulet, Anne Chalumeau, Laurent Kiger, Jouda Marouene, Valérie Jolaine, Jean-Marc Treluyer, Ambroise Marçais, Felipe Suarez, Olivier Hermine, Fulvio Mavilio, Emmanuelle Six, Wassim El Nemer, Pablo Bartolucci, Annarita Miccio, Marina Cavazzana
Journal: Blood (2021)
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
Authors: Jordi Diaz-Manera, Priya S Kishnani, Hani Kushlaf, Shafeeq Ladha, Tahseen Mozaffar, Volker Straub, Antonio Toscano, Ans T van der Ploeg, Kenneth I Berger, Paula R Clemens, Yin-Hsiu Chien, John W Day, Sergey Illarioshkin, Mark Roberts, Shahram Attarian, Joao Lindolfo Borges, Francoise Bouhour, Young Chul Choi, Sevim Erdem-Ozdamar, Ozlem Goker-Alpan, Anna Kostera-Pruszczyk, Kristina An Haack, Christopher Hug, Olivier Huynh-Ba, Judith Johnson, Nathan Thibault, Tianyue Zhou, Mazen M Dimachkie, Benedikt Schoser, Anthony Behin, Matthias Boentert, Gerson Carvalho, Nizar Chahin, Joel Charrow, Patrick Deegan, Hacer Durmus Tekce, Fanny Duval, Angela Genge, Ludwig Gutmann, Robert D Henderson, Julia B Hennermann, Tarekegn Hiwot, Derralynn Hughes, Amel Karaa, Chafic Karam, Alexandra Kautzky-Willer, Hirofumi Komaki, Pascal Laforet, Nicola Longo, Vera Malinova, Ricardo Maré, Clarisa Maxit, Eugen Mengel, Maurizio Gualtiero Moggio, Mária Judit Molnár, Tiziana Enrica Mongini, Aleksandra Nadaj-Pakleza, Andres Nascimento Osorio, Jean-Baptiste Noury, Acary Souza Bulle Oliveira, Yesim Parman, Loren Pena, Gauthier Remiche, Monica Sciacco, Perry B Shieh, Cheryl Smith, Thomas Stulnig, Frederic Taithe, Céline Tard, Mark Tarnopolsky, Matthias Vorgerd, Chester Whitley, Peter Young, Jorge Alonso-Pérez, Patricia Altemus, Anne-Catherine Aubé-Nathier, Jennifer B Avelar, Carrie Bailey, Can Ebru Bekircan-Kurt, Jenny Billy, Silvia Boschi, Kathryn E Brown, Laura Carrera Garcia, Lauren Chase, Hamilton Cirne, Loïc Danjoux, Jean-Baptiste Davion, Stephanie DeArmey, Ekaterina Fedotova, Eve Gandolfo, Zoltan Grosz, Dewi Guellec, Anne-Katrin Guettsches, Michela Guglieri, Erin Hatcher, Sina Helms, Miriam Hufgard-Leitner, Sergey A. Klyushnikov, Jacqui Langton, Lenka Linková, Nicolas Mavroudakis, Stella Mazurová, Madoka Mori, Louisa Müller-Miny, Olimpia Musumeci, Christopher S Nance, Daniel Natera-de Benito, Robert Neel, Gabriela A Niizawa, Lauren Noll, Erik Ortega, Mamatha Pasnoor, Vivien Pautot, Anna Potulska-Chromik, Alessia Pugliese, Claire Questienne, Margarida Ramos Lopes, David Reyes-Leiva, Michaela Riedl, Marcelo Francisco Rugiero, Emmanuelle Salort-Campana, Paulo Victor Sgobbi Souza, Guilhem Sole, Luca Solera, Suzara Souto Lopes, Sabine Specht, Jeffrey Statland, Andrea Swenson, Chong Yew Tan, Sónia Tizon, N A M E van der Beek, Harmke A. van Kooten, Marie Wencel, Stephan Wenninger, Fabien Zagnoli
Journal: The Lancet Neurology (2021)
Thrombosis Prophylaxis with Apixaban in Patients Treated with Asparaginase
Authors: Krishna Gundabolu, Vijaya R. Bhatt, Lynette M. Smith, Valerie K Shostrom, Lori J. Maness, Zaid S. Al-Kadhimi, Julie M. Vose, R. Gregory Bociek, Matthew A. Lunning, Avyakta Kallam, Christopher D'Angelo, Muhamed Baljevic, Apar K Ganti
Journal: Blood (2021)
Deficiency of RPS14 Beyond the Haploinsufficient Loss in Del(5q)
Authors: Vera Adema, Sunisa Kongkiatkamon, Laura Palomo, Wencke Walter, Stephan Hutter, Thomas LaFramboise, Maria Diez-Campelo, Mar Mallo, Blanca Xicoy, Manja Meggendorfer, Hetty E. Carraway, Claudia Haferlach, Valeria Visconte, Francesc Sole, John Barnard, Torsten Haferlach, Jaroslaw P. Maciejewski
Journal: Blood (2021)
Neural vulnerability and hurricane-related media are associated with post-traumatic stress in youth
Authors: Anthony Steven Dick, Karina Silva, Raul Gonzalez, Matthew T. Sutherland, Angela R. Laird, Wesley K. Thompson, Susan F. Tapert, Lindsay M. Squeglia, Kevin M. Gray, Sara Jo Nixon, Linda B. Cottler, Annette M. La Greca, Robin H. Gurwitch, Jonathan S. Comer
Journal: Nature Human Behaviour (2021)
Topics in AAV integration come front and center at ASGCT AAV Integration Roundtable
Authors: Denise E. Sabatino, Douglas M. McCarty
Journal: Molecular Therapy (2021)

Adeno-associated viral (AAV) vectors are in preclinical and clinical development to treat numerous genetic diseases with >100 ongoing clinical studies. In contrast to retroviral vectors with specific mechanisms for chromosomal integration, recombinant AAV (rAAV) primarily remains in an episomal form but can integrate at low frequency. These integration events occur by recombination at pre-existing chromosomal double-strand breaks (DSBs), and the distribution of these breaks largely explains the observed quasi-random integration profile. The episomal form provides long-term transgene expression in post-mitotic cells, including muscle, liver, and CNS. While it has been understood for decades that rAAV can integrate into the host genome, there remain many unanswered questions about the frequency of integration, profile within the genome, and potential risks associated with these integrations. Given the number of vector particles typically administered, even low integration rates can result in many integration events. The American Society of Gene and Cell Therapy recently held an AAV Integration Roundtable meeting (https://asgct.org/events/aav-roundtable) to discuss the current understanding of AAV integration and the challenges of assessing the potential risks associated with integration.
USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2
Authors: Arun Pandian Chandrasekaran, Kamini Kaushal, Chang-Hwan Park, Kye-Seong Kim, Suresh Ramakrishna
Journal: Theranostics (2021)

Background: The most commonly preferred chemotherapeutic agents to treat cancers are small-molecule drugs. However, the differential sensitivity of various cancer cells to small molecules and untargeted delivery narrow the range of potential therapeutic applications. The mechanisms responsible for drug resistance in a variety of cancer cells are also largely unknown. Several deubiquitinating enzymes (DUBs) are the main determinants of drug resistance in cancer cells. Methods: We used CRISPR-Cas9 to perform genome-scale knockout of the entire set of genes encoding ubiquitin-specific proteases (USPs) and systematically screened for DUBs resistant to the clinically evaluated anticancer compound YM155. A series of in vitro and in vivo experiments were conducted to reveal the relationship between USP32 and SLC35F2 on YM155-mediated DNA damage in cancer cells. Results: CRISPR-based dual-screening method identified USP32 as a novel DUB that governs resistance for uptake of YM155 by destabilizing protein levels of SLC35F2, a solute-carrier protein essential for the uptake of YM155. The expression of USP32 and SLC35F2 was negatively correlated across a panel of tested cancer cell lines. YM155-resistant cancer cells in particular exhibited elevated expression of USP32 and low expression of SLC35F2. Conclusion: Collectively, our DUB-screening strategy revealed a resistance mechanism governed by USP32 associated with YM155 resistance in breast cancers, one that presents an attractive molecular target for anti-cancer therapies. Targeted genome knockout verified that USP32 is the main determinant of SLC35F2 protein stability in vitro and in vivo, suggesting a novel way to treat tumors resistant to small-molecule drugs.
Novel Synthetic Lethal Targets for Myeloid Neoplasms with Loss of Chromosome 7
Authors: Minako Mori, Vera Adema, Carmelo Gurnari, Simona Pagliuca, Laila Terkawi, Waled Bahaj, Tariq Kewan, John Barnard, Valeria Visconte, Torsten Haferlach, Jaroslaw P. Maciejewski
Journal: Blood (2021)
Long-Term Clonal Dynamics upon Allogeneic Haematopoietic Stem Cell Transplantation Revealed Using Somatic Mutations As Clonal Tracking Marks in HSC Donor and Recipient Pairs
Authors: Michael Spencer Chapman, C. Matthias Wilk, Steffen Boettcher, Larisa V. Kovtonyuk, Emily Mitchell, Nicholas Williams, Jyoti Nangalia, Markus G Manz, Peter J. Campbell
Journal: Blood (2021)
The CIP2A–TOPBP1 axis safeguards chromosome stability and is a synthetic lethal target for BRCA-mutated cancer
Authors: Salomé Adam, Silvia Emma Rossi, Nathalie Moatti, Mara De Marco Zompit, Yibo Xue, Timothy F. Ng, Alejandro Álvarez-Quilón, Jessica Desjardins, Vivek Bhaskaran, Giovanni Martino, Dheva Setiaputra, Sylvie M. Noordermeer, Toshiro K. Ohsumi, Nicole Hustedt, Rachel K. Szilard, Natasha Chaudhary, Meagan Munro, Artur Veloso, Henrique Melo, Shou Yun Yin, Robert Papp, Jordan T. F. Young, Michael Zinda, Manuel Stucki, Daniel Durocher
Journal: Nature Cancer (2021)
Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with First Progression of Multiple Myeloma Refractory to Bortezomib and Lenalidomide. Final Report of the EMN011/HOVON114 Trial
Authors: Pieter Sonneveld, Sonja Zweegman, Michele Cavo, Kazem Nasserinejad, Annemiek Broyl, Rosella Troia, Ludek Pour, Sandra Croockewit, Paolo Corradini, Gerard M.J. Bos, Ka Lung Wu, Jolanda Droogendijk, Monique C. Minnema, Mario Boccadoro
Journal: Blood (2021)
CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia
Authors: Vincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, Gaia Alberti, Giulia Pianigiani, Roberta Rossi, Valerio Ciaurro, Marta Serafini, Maria Paola Martelli, Brunangelo Falini, Andrea Biondi, Sarah Tettamanti
Journal: Blood (2021)
CD45RO+ T-Cell Add Back and Prophylactic Blinatumomab Administration Post Tcrαβ/CD19-Depleted Haploidentical Transplantation in Pediatric Patients with High Risk Acute Leukemia
Authors: Swati Naik, Renee M. Madden, Ewelina Mamcarz, Ashok Srinivasan, Akshay Sharma, Aimee C Talleur, Rebecca Epperly, Amr Qudeimat, Ali Y Suliman, Esther A. Obeng, Mireya Paulina Velasquez, Diego Hijano, Gabriela Maron, Ying Li, Stephen Gottschalk, Brandon M Triplett
Journal: Blood (2021)
Effect of the COVID-19 Pandemic on Adolescents With Eating Disorders
Authors: Thonmoy Dey, Zachariah John Mansell, Jasmin Ranu
Journal: JAMA Pediatrics (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <scp>DAPA‐HF</scp>
Authors: Jawad H. Butt, Kieran F. Docherty, Pardeep S. Jhund, Rudolf A. de Boer, Michael Böhm, Akshay S. Desai, Jonathan G. Howlett, Silvio E. Inzucchi, Mikhail N. Kosiborod, Felipe A. Martinez, Jose C. Nicolau, Mark C. Petrie, Piotr Ponikowski, Olof Bengtsson, Anna Maria Langkilde, Morten Schou, Mikaela Sjöstrand, Scott D. Solomon, Marc S. Sabatine, John J.V. McMurray, Lars Køber
Journal: European Journal of Heart Failure (2021)
Bodiabaduge Ajith Senaka Jayasekara
Authors: M Mahendran
Journal: BMJ (2021)

Bodiabaduge Ajith Senaka Jayasekara (“Ajith,” fondly known as “BAS” to his large circle of friends) spent most of his career as a consultant physician in Colombo in the private sector. He did his postgraduate training in gastroenterology and general medicine at the Ninewells Hospitals in …
Characterization of Medical Conditions of Children with Sickle Cell Disease in the United States: Findings from the 2007-2018 National Health Interview Surveys (NHIS)
Authors: Joyce Gyamfi, Siphra Tampubolon, Justin Tyler Lee, Farha Islam, Temitope Ojo, Jumoke Opeyemi, Yuki Qiao, Andi Mai, Dorice Vieira, Emmanuel Peprah
Journal: Blood (2021)
Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms
Authors: Benjamin Diamond, Bachisio Ziccheddu, Eileen M Boyle, Kylee H Maclachlan, Juan Arango Ossa, Justin Taylor, Justin Watts, Sydney X. Lu, Venkata D Yellapantula, Christopher Famulare, Monika Chojnacka, Arjun Raj Rajanna, Emilia Mason, David G. Coffey, James E. Hoffman, Dickran Kazandjian, Terrence J Bradley, Menglei Zhu, Niccolo Bolli, Elli Papaemmanuil, Kelly L. Bolton, Michael Scordo, Oscar B Lahoud, Eytan M. Stein, Craig S. Sauter, Hani Hassoun, Sham Mailankody, Neha Korde, Malin Hultcrantz, Urvi A Shah, Gunjan L Shah, Jae H Park, Heather J Landau, Karuna Ganesh, Mikkael A. Sekeres, Stephen Nimer, David J. Chung, Caleb Ho, Mikhail Roshal, Alexander Lesokhin, Gareth J. Morgan, Ola Landgren, Francesco Maura
Journal: Blood (2021)
Industrialization of an Academic Miltenyi Prodigy-Based CAR T Process
Authors: Abigail Culshaw, Frederick Arce Vargas, Gerardo Santiago Toledo, Claire Roddie, Paul Shaughnessy, Virginie Cerec, Kevin Duffy, Serena Perna, Wolfram Brugger, Michael Merges, Martin Pule
Journal: Blood (2021)
Consumption of coffee and tea and risk of developing stroke, dementia, and poststroke dementia: A cohort study in the UK Biobank
Authors: Yuan Zhang, Hongxi Yang, Shu Li, Wei-dong Li, Yaogang Wang
Journal: PLoS Medicine (2021)

Background Previous studies have revealed the involvement of coffee and tea in the development of stroke and dementia. However, little is known about the association between the combination of coffee and tea and the risk of stroke, dementia, and poststroke dementia. Therefore, we aimed to investigate the associations of coffee and tea separately and in combination with the risk of developing stroke and dementia. Methods and findings This prospective cohort study included 365,682 participants (50 to 74 years old) from the UK Biobank. Participants joined the study from 2006 to 2010 and were followed up until 2020. We used Cox proportional hazards models to estimate the associations between coffee/tea consumption and incident stroke and dementia, adjusting for sex, age, ethnicity, qualification, income, body mass index (BMI), physical activity, alcohol status, smoking status, diet pattern, consumption of sugar-sweetened beverages, high-density lipoprotein (HDL), low-density lipoprotein (LDL), history of cancer, history of diabetes, history of cardiovascular arterial disease (CAD), and hypertension. Coffee and tea consumption was assessed at baseline. During a median follow-up of 11.4 years for new onset disease, 5,079 participants developed dementia, and 10,053 participants developed stroke. The associations of coffee and tea with stroke and dementia were nonlinear ( P for nonlinear &lt;0.01), and coffee intake of 2 to 3 cups/d or tea intake of 3 to 5 cups/d or their combination intake of 4 to 6 cups/d were linked with the lowest hazard ratio (HR) of incident stroke and dementia. Compared with those who did not drink tea and coffee, drinking 2 to 3 cups of coffee and 2 to 3 cups of tea per day was associated with a 32% (HR 0.68, 95% CI, 0.59 to 0.79; P &lt; 0.001) lower risk of stroke and a 28% (HR, 0.72, 95% CI, 0.59 to 0.89; P = 0.002) lower risk of dementia. Moreover, the combination of coffee and tea consumption was associated with lower risk of ischemic stroke and vascular dementia. Additionally, the combination of tea and coffee was associated with a lower risk of poststroke dementia, with the lowest risk of incident poststroke dementia at a daily consumption level of 3 to 6 cups of coffee and tea (HR, 0.52, 95% CI, 0.32 to 0.83; P = 0.007). The main limitations were that coffee and tea intake was self-reported at baseline and may not reflect long-term consumption patterns, unmeasured confounders in observational studies may result in biased effect estimates, and UK Biobank participants are not representative of the whole United Kingdom population. Conclusions We found that drinking coffee and tea separately or in combination were associated with lower risk of stroke and dementia. Intake of coffee alone or in combination with tea was associated with lower risk of poststroke dementia.
Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): A Subgroup Analysis of Griffin
Authors: Larry D. Anderson, Jonathan L. Kaufman, Jacob P. Laubach, Douglas W. Sborov, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca W. Silbermann, Luciano J. Costa, Nitya Nathwani, Nina Shah, Naresh Bumma, Sarah A. Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M. Wildes, Robert Z. Orlowski, Kenneth H. Shain, Andrew J. Cowan, Huiling Pei, Annelore Cortoos, Sharmila Patel, J Blake Bartlett, Jessica Vermeulen, Thomas S. Lin, Peter M. Voorhees, Paul G. Richardson
Journal: Blood (2021)
Cryopreservation of Allogeneic Hematopoietic Cell Grafts Did Not Adversely Affect Early Post-Transplant Survival during the First Six Months of the COVID-19 Pandemic
Authors: Steven Devine, Michelle Kuxhausen, Stephen R. Spellman, Caitrin Fretham, Kwang Woo Ahn, Heather E. Stefanski, Jeffery J. Auletta, Brent R. Logan, Bronwen E. Shaw
Journal: Blood (2021)
U2AF1 and Other Splicing Factor Gene Mutations in Telomere Biology Disorders Are Associated with Hematologic Neoplasia and Worse Overall Survival
Authors: Emma M. Groarke, Fernanda Gutierrez-Rodrigues, Xiaoyang Ma, Bhavisha A. Patel, Nina Spitofsky, Paul V. Browne, Kelly S. Chien, Colin O. Wu, Courtney D. DiNardo, Simona Colla, Rodrigo T. Calado, Neal S. Young
Journal: Blood (2021)
Belantamab in Combination with Dexamethasone in Patients with Triple-Class Relapsed/Refractory Multiple Myeloma
Authors: Tahani Atieh, Shebli Atrash, Meera Mohan, Leyla Shune, Zahra Mahmoudjafari, Julie Quick, Justin Riffel, Joseph P. McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah, Nausheen Ahmed, Wei Cui, Anne Wishna
Journal: Blood (2021)
Erythrocyte-mimicking subcutaneous platform with a laser-controlled treatment against diabetes
Authors: Jinsong Shao, Lingzi Feng, Qingyu Zhao, Chao Chen, Jia Li, Qian Ma, Xiaohan Jiang, Ying Sun, Yanguang Yang, Haiying Gu, Yong Hu, Donglin Xia
Journal: Journal of Controlled Release (2021)
Ambiguous Diagnosis of Nodal T-Cell Lymphomas with T-Follicular Helper (TFH) Phenotype and Hodgkin Lymphoma - a Multicenter Pilot Study
Authors: Esther Wei Yin Chang, Grace Fangmin Tan, Si Ting Goh, Talia Li Yin Lim, Shin Yeu Ong, Chandramouli Nagarajan, Nicholas Francis Grigoropoulos, Sanjay De Mel, Michelle Poon, Anand Devaprasath Jeyasekharan, Jianbang Chiang, Ya Hwee Tan, Valerie Yang, Eileen Yi Ling Poon, Nagavalli Somasundaram, Mohamad Farid, Miriam Tao, Chee Leong Cheng, Leonard Hwan Cheong Tan, Siok Bian Ng, Soo Yong Tan, Daryl Ming Zhe Cheah, Dachuan Huang, Jing Quan Lim, Soon Thye Lim, Choon Kiat Ong, Jason Yongsheng Chan
Journal: Blood (2021)